Brief: ADC Therapeutics Announces Initial Data From Investigator-Initiated Phase 2 Clinical Trial Of Zynlonta In Patients With Relapsed/Refractory Marginal Zone Lymphoma

Adc Therapeutics

06/05/2024 11:06

May 6 (Reuters) - ADC Therapeutics SA  ADCT.N :
    * ADC THERAPEUTICS ANNOUNCES INITIAL DATA FROM
INVESTIGATOR-INITIATED PHASE 2 CLINICAL TRIAL OF ZYNLONTA® IN
PATIENTS WITH RELAPSED/REFRACTORY MARGINAL ZONE LYMPHOMA
    * ZYNLONTA WAS GENERALLY WELL-TOLERATED AND SAFETY WAS
CONSISTENT
WITH KNOWN PROFILE
    * ZYNLONTA WAS GENERALLY WELL-TOLERATED AND SAFETY WAS
CONSISTENT
WITH KNOWN PROFILE
    * ALL PATIENTS ACHIEVING RESPONSES MAINTAINED THEM AT TIME
OF DATA
CUTOFF

Source text for Eikon:  ID:nGNX7TTn98 
Further company coverage:  ADCT.N 

 ((Reuters.Briefs@thomsonreuters.com;))